Anonymous
Guest
Anonymous
Guest
I would consider myself a pretty well informed vaccine industry insider who has worked for both GSK and Merck (not a sales rep), here is my perspective on the Novartis vaccine situation. First, let me say I understand what the Novartis pharma reps are thinking at this point and this post is not to attack them or burst their hope of getting those new vaccine jobs. Rather, my post is too add to the meaningful discussion. I certainly can't blame any pharma rep for hoping this is their opportunity to get out of being a pharma rep and into a growing vaccine market that has more direct sales responsibility and is a safer place due to robust pipelines, especially the one at Novartis.
My thoughts are that Novartis is going to get this expansion right, let me explain further. I really feel they are going to hire the right people with the right mix of experience (private and public sector vaccine experience) and learn from the mistakes of other companies and their commercial models and vaccine product launches. They clearly have taken their time with the expansion so they don't jump the gun like Merck and even GSK, having people doing market development for 6 months with no product. They also have already cherry picked PED marketing talent from Merck to head up Menveo (I am not naming names or initials but those who work inside at Merck know who it is) I won't go into detail on the other mistakes at Merck but any Merck vaccine person reading this knows exactly what I am referring too in the sense of ruining a great division by mixing pharma and vaccines together and bringing in pharma leadership with zero vaccine experience. GSK apparently is shaking things up as well but is faced with issues due to product delays etc.
It will also be no surprise to see a certain recently displaced senior level person from Merck Vaccines as one of the directors of sales. In fact sources I have nearly confirmed that one of the three directors is in fact a former Merck Ped SBD (again not naming names) who will run the West region. With that said, I agree totally with the poster who points out the differences of pharma vs. vaccines, and to my point of Novartis getting this right, I think that the new vaccine Novartis district managers will consist of Merck, GSK, and SA vaccine managers. It will be easy to find Ped and PCP vaccine managers at Merck who are willing to leave for the shear opportunity of being in a small division again, new leadership and having new product bonus potential again which was so nice during all of Merck's vaccine launches. I am sure the same can be said for GSK vaccine managers who want a change or see the HPV battle as already lost due to delay perceptions. Perhaps they keep a few high potential Novartis pharma managers who have an interest in the job or an inside connection. It is my opinion though that pharma reps with no vaccine experience have little to no chance since it is my belief that the district managers and directors know the unique differences between pharma/vaccines and will not make that mistake. In this job environment and with all the vaccine experience that will likely apply for the jobs it would make no sense to hire a pharma rep and wait 6-8 months for them to figure it out and learn the in's and out's of the vaccine business. There is also instant credibility going into an office with vaccine knowledge. During Merck's expansion they moved pharma people over and while some "got it" and loved it when it came to selling vaccines, many people struggled with the transition and didn't like closing a customer for an order of x doses on the spot and preferred the softer pharma sale and being in clusters of 4 people with very limited direct accountability. In vaccines, numbers are instant and you likely the only person promoting your product so there is no hiding and waiting 3 months for data. There are going to be people, likely pharma reps, who disagree with me and thats fine, I would just simply say you are grossly misinformed of the differences of pharma/vaccines. I do recognize there are really good sales people "stuck" in pharma sales and I feel your pain, for I was in your position back in the day but was very lucky to break out with persistence, luck, politics and performance.
This will be an interesting case study looking back to see if Novartis gets this right, again I think they will. However, if they don't get it right, they have no one to blame because they had the talent pool and recent launch examples to model and learn from. I wish everyone luck in these challenging times and for those who apply and don't the jobs at Novartis, remember that the vaccine reps and managers from GSK, SA, and Merck will likely need to be replaced so there will still be opportunities to get into vaccines elsewhere. Good luck!
Nice try.